Support for KGBD Podcasts comes from Landmark College, offering a fully online graduate-level

certificate in learning differences in neurodiversity program. Visit landmark.edu slash certificate to learn more.

Support for Forum comes from Broadway SF, presenting Parade, the musical revival based on a true story.

From three-time Tony-winning composer Jason Robert Brown comes the story of Leo and Lucille Frank,

a newlywed Jewish couple struggling to make a life in Georgia.

When Leo is accused of an unspeakable crime, it propels them into an unimaginable test of faith, humanity, justice, and

devotion. The riveting and gloriously hopeful parade plays the Orpheum Theater for three weeks only,

May 20th through June 8th. Tickets on sale now at Broadwaysf.com.

From KQED.

From KQED.

From KQED in San Francisco, I'm Alexis Madrigal.

Sickle cell anemia is a painful, painful disease that disproportionately affects black people.

Over the decades that it's been recognized by Western science, it has not received adequate funding to come up with new treatments.

Patients often have very poor quality of life as they struggle with the pain that the blood disease inflicts.

But a major collaboration between California academic institutions promises to use the revolutionary gene editing technology known as CRISPR to correct the genetic mutation that causes the disease.

We'll talk with a patient and two doctors working on the treatment.

And then we'll hear about the plight of outdoor workers who should be but often aren't protected by California labor laws. That's all next

after this news.

Welcome to Forum. I'm Alexis Madrigal. Sickle cell disease is a red blood cell disorder that is debilitating, painful, and leads to other medical problems like infections and strokes.

It is most prevalent among black people and patients have struggled to access basic care.

Later, we'll be joined by a sickle cell patient at UCSF who's getting a blood transfusion as we speak.

But we're going to start today with two members of the team working on the new CRISPR trial.

...